所有经典霍奇金淋巴瘤 (CHL) 病例中有 20% 会复发，尤其是在国际预后评分 (IPS) 较高的晚期阶段。细胞毒性T淋巴细胞相关蛋白4（CTLA-4）是一种能够抑制免疫反应并与肿瘤侵袭性相关的调节分子。本研究旨在确定晚期 CHL 和 IPS 中 CTLA-4 表达的关系，将其确定为潜在的治疗靶点。在晚期 CHL 中，IPS 高的组表现出明显更高的平均 CTLA-4 表达。 IPS 低的组 (p = 0.003)。 Hb 水平 < 10.5 g/dl、白细胞计数 > 15,000/μL、淋巴细胞计数 < 8%、白蛋白水平 < 4 g/dl 和第 4 阶段的组表现出较高的 CTLA -4 表达高于其他组，尽管仅白细胞计数和分期显示出统计学显着性（p = 0.004 和 p = 0.020）。结节性硬化症的平均 CTLA-4 表达为 239.84±76.36，混合细胞型为 293.95±147.94，淋巴细胞耗尽型为 271.4±23.56，富含淋巴细胞亚型为 225.2。结果表明，CTLA-4 表达与晚期 CHL IPS 中的不良预后因素相关，支持免疫检查点在癌症进展中发挥作用的观点。© 2024。作者。

Twenty percent of all classical Hodgkin lymphoma (CHL) cases relapse and recur, especially in advanced stages with a high International Prognostic Score (IPS). Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a regulatory molecule that can inhibit the immune response and is related to tumor aggressiveness. This study aimed to determine the relationship between CTLA-4 expression in advanced-stage CHL and IPS, identifying it as a potential therapy target.In advanced-stage CHL, the group with a high IPS exhibited significantly higher mean CTLA-4 expression compared to the group with a low IPS (p = 0.003).The group with Hb level < 10.5 g/dl, leukocyte count > 15,000/µL, lymphocyte count < 8%, albumin level < 4 g/dl, and stage 4 exhibited higher CTLA-4 expression than the other group, although only leukocyte count and stage showed statistical significance (p = 0.004 and p = 0.020). Mean CTLA-4 expression was 239.84 ± 76.36 for nodular sclerosis, 293.95 ± 147.94 for mixed cellularity, 271.4 ± 23.56 for lymphocyte depleted, and 225.2 for lymphocyte-rich subtypes. The results suggest that CTLA-4 expression is associated with adverse prognostic factors in the IPS for advanced-stage CHL, supporting the notion that immune checkpoints play a role in cancer progression.© 2024. The Author(s).